Advertisement

Ontology-Based Vaccine Adverse Event Representation and Analysis

  • Jiangan Xie
  • Yongqun He
Chapter
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1028)

Abstract

Vaccine is the one of the greatest inventions of modern medicine that has contributed most to the relief of human misery and the exciting increase in life expectancy. In 1796, an English country physician, Edward Jenner, discovered that inoculating mankind with cowpox can protect them from smallpox (Riedel S, Edward Jenner and the history of smallpox and vaccination. Proceedings (Baylor University. Medical Center) 18(1):21, 2005). Based on the vaccination worldwide, we finally succeeded in the eradication of smallpox in 1977 (Henderson, Vaccine 29:D7–D9, 2011). Other disabling and lethal diseases, like poliomyelitis and measles, are targeted for eradication (Bonanni, Vaccine 17:S120–S125, 1999).

Although vaccine development and administration are tremendously successful and cost-effective practices to human health, no vaccine is 100% safe for everyone because each person reacts to vaccinations differently given different genetic background and health conditions. Although all licensed vaccines are generally safe for the majority of people, vaccinees may still suffer adverse events (AEs) in reaction to various vaccines, some of which can be serious or even fatal (Haber et al., Drug Saf 32(4):309–323, 2009). Hence, the double-edged sword of vaccination remains a concern.

To support integrative AE data collection and analysis, it is critical to adopt an AE normalization strategy. In the past decades, different controlled terminologies, including the Medical Dictionary for Regulatory Activities (MedDRA) (Brown EG, Wood L, Wood S, et al., Drug Saf 20(2):109–117, 1999), the Common Terminology Criteria for Adverse Events (CTCAE) (NCI, The Common Terminology Criteria for Adverse Events (CTCAE). Available from: http://evs.nci.nih.gov/ftp1/CTCAE/About.html. Access on 7 Oct 2015), and the World Health Organization (WHO) Adverse Reactions Terminology (WHO-ART) (WHO, The WHO Adverse Reaction Terminology – WHO-ART. Available from: https://www.umc-products.com/graphics/28010.pdf), have been developed with a specific aim to standardize AE categorization. However, these controlled terminologies have many drawbacks, such as lack of textual definitions, poorly defined hierarchies, and lack of semantic axioms that provide logical relations among terms. A biomedical ontology is a set of consensus-based and computer and human interpretable terms and relations that represent entities in a specific biomedical domain and how they relate each other. To represent and analyze vaccine adverse events (VAEs), our research group has initiated and led the development of a community-based ontology: the Ontology of Adverse Events (OAE) (He et al., J Biomed Semant 5:29, 2014). The OAE has been found to have advantages to overcome the drawbacks of those controlled terminologies (He et al., Curr Pharmacol Rep :1–16. doi:10.1007/s40495-016-0055-0, 2014). By expanding the OAE and the community-based Vaccine Ontology (VO) (He et al., VO: vaccine ontology. In The 1st International Conference on Biomedical Ontology (ICBO-2009). Nature Precedings, Buffalo. http://precedings.nature.com/documents/3552/version/1; J Biomed Semant 2(Suppl 2):S8; J Biomed Semant 3(1):17, 2009; Ozgur et al., J Biomed Semant 2(2):S8, 2011; Lin Y, He Y, J Biomed Semant 3(1):17, 2012), we have also developed the Ontology of Vaccine Adverse Events (OVAE) to represent known VAEs associated with licensed vaccines (Marcos E, Zhao B, He Y, J Biomed Semant 4:40, 2013).

In this book chapter, we will first introduce the basic information of VAEs, VAE safety surveillance systems, and how to specifically query and analyze VAEs using the US VAE database VAERS (Chen et al., Vaccine 12(10):960–960, 1994). In the second half of the chapter, we will introduce the development and applications of the OAE and OVAE. Throughout this chapter, we will use the influenza vaccine Flublok as the vaccine example to launch the corresponding elaboration (Huber VC, McCullers JA, Curr Opin Mol Ther 10(1):75–85, 2008). Flublok is a recombinant hemagglutinin influenza vaccine indicated for active immunization against disease caused by influenza virus subtypes A and type B. On January 16, 2013, Flublok was approved by the FDA for the prevention of seasonal influenza in people 18 years and older in the USA. Now, more than 3 years later, an exploration of the reported AEs associated with this vaccine is urgently needed.

Keywords

Vaccine Administration Ontology Adverse event Flublok 

Notes

Acknowledgment

We appreciate Mr. Jordan Rinder’s editorial review and comments.

References

  1. 1.
    Riedel S (2005) Edward Jenner and the history of smallpox and vaccination. Proceedings (Baylor University. Medical Center) 18(1):21Google Scholar
  2. 2.
    Henderson DA (2011) The eradication of smallpox – an overview of the past, present, and future. Vaccine 29:D7–D9CrossRefPubMedGoogle Scholar
  3. 3.
    Bonanni P (1999) Demographic impact of vaccination: a review. Vaccine 17:S120–S125CrossRefPubMedGoogle Scholar
  4. 4.
    Haber P et al (2009) Vaccines and Guillain-Barre syndrome. Drug Saf 32(4):309–323CrossRefPubMedGoogle Scholar
  5. 5.
    Brown EG, Wood L, Wood S (1999) The medical dictionary for regulatory activities (MedDRA). Drug Saf 20(2):109–117CrossRefPubMedGoogle Scholar
  6. 6.
    NCI. The Common Terminology Criteria for Adverse Events (CTCAE). Available from: http://evs.nci.nih.gov/ftp1/CTCAE/About.html. Access on 7 Oct 2015
  7. 7.
    WHO. The WHO Adverse Reaction Terminology – WHO-ART. Available from: https://www.umc-products.com/graphics/28010.pdf
  8. 8.
    He YQ et al (2014) OAE: the ontology of adverse events. J Biomed Semant 5:29CrossRefGoogle Scholar
  9. 9.
    He Y (2016) Ontology-based vaccine and drug adverse event representation and theory-guided systematic causal network analysis toward integrative pharmacovigilance research. Curr Pharmacol Rep :1–16. doi: 10.1007/s40495-016-0055-0). In press
  10. 10.
    He Y, et al (2009) VO: vaccine ontology. In The 1st International Conference on Biomedical Ontology (ICBO-2009). Nature Precedings, Buffalo. http://precedings.nature.com/documents/3552/version/1
  11. 11.
    Ozgur A et al (2011) Mining of vaccine-associated IFN-gamma gene interaction networks using the vaccine ontology. J Biomed Semant 2(2):S8CrossRefGoogle Scholar
  12. 12.
    Lin Y, He Y (2012) Ontology representation and analysis of vaccine formulation and administration and their effects on vaccine immune responses. J Biomed Semant 3(1):17CrossRefGoogle Scholar
  13. 13.
    Marcos E, Zhao B, He Y (2013) The Ontology of Vaccine Adverse Events (OVAE) and its usage in representing and analyzing adverse events associated with US-licensed human vaccines. J Biomed Semant 4:40CrossRefGoogle Scholar
  14. 14.
    Chen RT et al (1994) The vaccine adverse event reporting system (Vaers) (Vol 12, Pg 542, 1994). Vaccine 12(10):960–960Google Scholar
  15. 15.
    Huber VC, McCullers JA (2008) FluBlok, a recombinant influenza vaccine. Curr Opin Mol Ther 10(1):75–85PubMedGoogle Scholar
  16. 16.
    Varricchio F et al (2004) Understanding vaccine safety information from the vaccine adverse event reporting system. Pediatr Infect Dis J 23(4):287–294CrossRefPubMedGoogle Scholar
  17. 17.
    Sarntivijai S et al (2012) Ontology-based combinatorial comparative analysis of adverse events associated with killed and live influenza vaccines. PLoS One 7(11):e49941CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Sarntivijai S et al (2016) Linking MedDRA®-coded clinical phenotypes to biological mechanisms by the ontology of adverse events: a pilot study on tyrosine kinase inhibitors. Drug Saf:1–11Google Scholar
  19. 19.
    Evans SJW, Waller PC, Davis S (2001) Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 10(6):483–486CrossRefPubMedGoogle Scholar
  20. 20.
    Banks D et al (2005) Comparing data mining methods on the VAERS database. Pharmacoepidemiol Drug Saf 14(9):601–609CrossRefPubMedGoogle Scholar
  21. 21.
    Woo EJ et al (2008) Effects of stratification on data mining in the US Vaccine Adverse Event Reporting System (VAERS). Drug Saf 31(8):667–674CrossRefPubMedGoogle Scholar
  22. 22.
    Pearson K (1900) X. on the criterion that a given system of deviations from the probable in the case of a correlated system of variables is such that it can be reasonably supposed to have arisen from random sampling. Lond, Edinb Dublin Philos Mag J Sci 50(302):157–175CrossRefGoogle Scholar
  23. 23.
    Fisher RA (1922) On the interpretation of χ 2 from contingency tables, and the calculation of P. J R Stat Soc 85(1):87–94CrossRefGoogle Scholar
  24. 24.
    Yates F (1934) Contingency tables involving small numbers and the χ2 test. Suppl J R Stat Soc 1:217–235CrossRefGoogle Scholar
  25. 25.
    Xie J et al (2016) Differential adverse event profiles associated with BCG as a preventive tuberculosis vaccine or therapeutic bladder cancer vaccine identified by comparative ontology-based VAERS and literature meta-analysis. PLoS One 11(10):e0164792CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Xie J et al (2016) Statistical and ontological analysis of adverse events associated with monovalent and combination vaccines against hepatitis A and B diseases. Sci Rep 6Google Scholar
  27. 27.
    Brown EG (2003) Methods and pitfalls in searching drug safety databases utilising the Medical Dictionary for Regulatory Activities (MedDRA). Drug Saf 26(3):145–158CrossRefPubMedGoogle Scholar
  28. 28.
    Xiang Z, et al (2011) Ontobee: a linked data server and browser for ontology terms. In the 2nd International Conference on Biomedical Ontologies (ICBO). CEUR Workshop Proceedings, New YorkGoogle Scholar
  29. 29.
    Cox MM et al (2015) Safety, efficacy, and immunogenicity of Flublok in the prevention of seasonal influenza in adults. Ther Adv Vaccines 3(4):97–108CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Poland GA et al (2007) Heterogeneity in vaccine immune response: the role of immunogenetics and the emerging field of vaccinomics. Clin Pharmacol Ther 82(6):653–664CrossRefPubMedGoogle Scholar
  31. 31.
    Poland GA, Ovsyannikova IG, Jacobson RM (2009) Application of pharmacogenomics to vaccines. Pharmacogenomics 10(5):837–852CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    He Y (2014) Ontology-supported research on vaccine efficacy, safety and integrative biological networks. Expert Rev Vaccines 13(7):825–841CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Xiang Z et al (2010) OntoFox: web-based support for ontology reuse. BMC Res Notes 3(1):175CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2017

Authors and Affiliations

  1. 1.School of BioinformaticsChongqing University of Posts and TelecommunicationsChongqingChina
  2. 2.University of Michigan Medical SchoolAnn ArborUSA

Personalised recommendations